Weiss Ratings restated their sell (e+) rating on shares of Aclarion (NASDAQ:ACON – Free Report) in a report published on Friday morning,Weiss Ratings reports.
Aclarion Stock Performance
ACON opened at $7.55 on Friday. Aclarion has a 52-week low of $6.20 and a 52-week high of $3,499.51. The firm’s 50-day moving average price is $7.75 and its 200-day moving average price is $7.49.
Aclarion (NASDAQ:ACON – Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($2.75) EPS for the quarter, missing analysts’ consensus estimates of ($2.26) by ($0.49). Aclarion had a negative return on equity of 83.63% and a negative net margin of 11,238.59%.The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect that Aclarion will post -263.33 EPS for the current year.
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Featured Stories
- Five stocks we like better than Aclarion
- What is the Shanghai Stock Exchange Composite Index?
- PulteGroup Is Down But Not Out—Here’s What Wall Street Missed
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Cleveland-Cliffs Breaks to New Highs on Earnings, More Upside?
- Insider Buying Explained: What Investors Need to Know
- Is Landstar the Next Big Winner in Transportation Stocks?
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
